Tian Zhang, Director of Clinical Research at UT Southwestern Medical Center, shared a post on X:
“Femke Burgers with one of first neoadjuvant trials in Kidney cancer.
NESCIO — 6 weeks ipi-nivo and relatlimab-nivo had few pathologic complete responders. Important to bring effective tx into neoadjuvant space.”
You Can Also Read:
ESMO 2025 Day 1 Highlights Not to Miss
ESMO 2025 Day 2 Highlights Not to Miss
